Receptor Binding Assays &
Densitometry Tools

BIOQUANT Life Science includes Densitometry Tools for receptor binding assays, quantitative autoradiography, in-situ hybridization histochemistry, and whole-body autoradiography, and grayscale digital cameras/image support.

Selected Software Features

  • Curve fitting for Density Calibrations using seven types of curves including exponential, linear, logarithmic, power, and N-degree polynomial.

  • Calibration curve shows R2 for the curve and relative error for each standard value

  • Data, histograms, and pseudocolor palettes reported in calibrated units

  • Pseudocolor palettes automatically generated from standards

  • Easily save pseudocolor images with overlaid pseudocolor calibration bars

  • Place, move, and erase sampling areas in preview mode before saving data

  • Automatic mode records data for objects that meet threshold and geometric filter criteria

Representative Applications

  • Receptor Binding Assays

  • Quantitative Autoradiography

  • In-situ Hybridization Histochemistry

  • Whole-body Autoradiography

  • Genome Size Quantification by Feulgen Staining

Main Supported Hardware

  • Use Fuji BAS 5000 Phosphorimager to generate IMG + INF files that can be opened in BIOQUANT.

  • Capture direct, live monochrome images using the QImaging RETIGA EXI Monochrome Camera.

  • Digitize film with high-resolution, 4+ OD scanner to generate a 16-bit high resolution TIFF files that can be opened in BIOQUANT.

Recent Citations of BIOQUANT in Receptor Binding

Featured
osteonecrosis
femoral head, osteonecrosis, avascular necrosis, Legg-Calve-Perthes Disease, interleukin-6, receptor inhibitor, tocilizumab
Anti‐Interleukin‐6 Therapy Decreases Hip Synovitis and Bone Resorption and Increases Bone Formation Following Ischemic Osteonecrosis of the Femoral Head
osteonecrosis
femoral head, osteonecrosis, avascular necrosis, Legg-Calve-Perthes Disease, interleukin-6, receptor inhibitor, tocilizumab

Legg‐Calvé‐Perthes disease (LCPD) is a juvenile form of ischemic femoral head osteonecrosis, which produces chronic hip synovitis, permanent femoral head deformity, and premature osteoarthritis. Currently, there is no medical therapy for LCPD. Interleukin‐6 (IL‐6) is significantly elevated in the synovial fluid of patients with LCPD. We hypothesize that IL‐6 elevation promotes chronic hip synovitis and impairs bone healing after ischemic osteonecrosis.

osteonecrosis
femoral head, osteonecrosis, avascular necrosis, Legg-Calve-Perthes Disease, interleukin-6, receptor inhibitor, tocilizumab